---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-044830"
form_type: "8-K"
ticker: "CALC"
cik: "0001534133"
company_name: "CalciMedica, Inc."
filed_at: "2025-03-04T23:59:59+00:00"
generated_at: "2026-05-25T13:54:20.144577+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CalciMedica reports 62.7% relative mortality reduction with Auxora in AKI subset of CARDEA trial

## Summary
- In patients with AKI (eGFR ≤60) plus respiratory failure, Auxora reduced day-30 mortality by 62.7% vs placebo; 17.4% vs 46.7% died.
- Absolute mortality reduction of 29.3% in AKI subset; full study showed 56.3% relative reduction (p=0.017) with 9.9% absolute reduction.
- Preclinical and biomarker data supporting CRAC channel inhibition in AKI were also presented.
- Ongoing Phase 2 KOURAGE trial in Stage 2/3 AKI with hypoxemic respiratory failure is expected to read out in 2025.

## SEC filing metadata
- accession: 0001193125-25-044830
- form_type: 8-K
- ticker: CALC
- cik: 0001534133
- company_name: CalciMedica, Inc.
- filed_at: 2025-03-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534133/000119312525044830/0001193125-25-044830-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534133/000119312525044830/d824505d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-044830
- JSON: https://secwatch.observer/filing/0001193125-25-044830.json
- Plain text: https://secwatch.observer/filing/0001193125-25-044830.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.